Cited 0 times in
New brain metastases after whole-brain radiotherapy of initial brain metastases in breast cancer patients: the significance of molecular subtypes (KROG 16-12)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김용배 | - |
dc.contributor.author | 장지석 | - |
dc.date.accessioned | 2021-12-28T17:21:53Z | - |
dc.date.available | 2021-12-28T17:21:53Z | - |
dc.date.issued | 2021-04 | - |
dc.identifier.issn | 0167-6806 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/187067 | - |
dc.description.abstract | Purpose: To identify the risk factors leading to new brain metastases (BM) following brain-directed treatment for initial BM resulting from breast cancer (BC). Methods: In this multi-institutional study, 538 BC patients with available follow-up imaging after brain-directed treatment for initial BM were analyzed. Tumor molecular subtypes were classified as follows: hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-, n = 136), HER2-positive (HER2+, n = 253), or triple-negative BC (TNBC, n = 149). Results: In 37.4% of patients, new BM emerged at a median of 10.5 months after brain-directed treatment for initial BM. The 1-year actuarial rate of new BM for HR+/HER2-, HER2+, and TNBC were 51.9%, 44.0%, and 69.6%, respectively (p = 0.008). Initial whole-brain radiotherapy (WBRT) reduced new BM rates (22.5% reduction at 1 year, p < 0.001) according to molecular subtype (HR+/HER2-, 42% reduction at 1 year, p < 0.001; HER2+, 18.5%, p = 0.004; TNBC, 16.9%, p = 0.071). Multivariate analysis revealed an increased risk of new BM for the following factors: shorter intervals between primary BC diagnoses and BM (p = 0.031); TNBC (relative to HR+/HER2-) (p = 0.016); presence of extracranial metastases (p = 0.019); number of BM (>4) (p < 0.001); and BM in both tentorial regions (p = 0.045). Anti-HER2 therapy in HER2+ patients (p = 0.013) and initial use of WBRT (p < 0.001) significantly lowered new BM development. Conclusions: Tumor molecular subtypes were associated with both rates of new BM development and the effectiveness of initial WBRT. Anti-HER2 therapy in HER2+ patients significantly lowered new BM occurrence. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Kluwer Academic | - |
dc.relation.isPartOf | BREAST CANCER RESEARCH AND TREATMENT | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Brain / metabolism | - |
dc.subject.MESH | Brain Neoplasms* / radiotherapy | - |
dc.subject.MESH | Breast Neoplasms* / radiotherapy | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Receptor, ErbB-2 / genetics | - |
dc.subject.MESH | Receptor, ErbB-2 / metabolism | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Triple Negative Breast Neoplasms* / radiotherapy | - |
dc.title | New brain metastases after whole-brain radiotherapy of initial brain metastases in breast cancer patients: the significance of molecular subtypes (KROG 16-12) | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Radiation Oncology (방사선종양학교실) | - |
dc.contributor.googleauthor | Jae Sik Kim | - |
dc.contributor.googleauthor | Kyubo Kim | - |
dc.contributor.googleauthor | Wonguen Jung | - |
dc.contributor.googleauthor | Kyung Hwan Shin | - |
dc.contributor.googleauthor | Seock-Ah Im | - |
dc.contributor.googleauthor | Hee-Jun Kim | - |
dc.contributor.googleauthor | Yong Bae Kim | - |
dc.contributor.googleauthor | Jee Suk Chang | - |
dc.contributor.googleauthor | Jee Hyun Kim | - |
dc.contributor.googleauthor | Doo Ho Choi | - |
dc.contributor.googleauthor | Yeon Hee Park | - |
dc.contributor.googleauthor | Dae Yong Kim | - |
dc.contributor.googleauthor | Tae Hyun Kim | - |
dc.contributor.googleauthor | Byung Ock Choi | - |
dc.contributor.googleauthor | Sea-Won Lee | - |
dc.contributor.googleauthor | Suzy Kim | - |
dc.contributor.googleauthor | Jeanny Kwon | - |
dc.contributor.googleauthor | Ki Mun Kang | - |
dc.contributor.googleauthor | Woong-Ki Chung | - |
dc.contributor.googleauthor | Kyung Su Kim | - |
dc.contributor.googleauthor | Won Sup Yoon | - |
dc.contributor.googleauthor | Jin Hee Kim | - |
dc.contributor.googleauthor | Jihye Cha | - |
dc.contributor.googleauthor | Yoon Kyeong Oh | - |
dc.contributor.googleauthor | In Ah Kim | - |
dc.identifier.doi | 10.1007/s10549-020-06043-0 | - |
dc.contributor.localId | A00744 | - |
dc.contributor.localId | A04658 | - |
dc.relation.journalcode | J00403 | - |
dc.identifier.eissn | 1573-7217 | - |
dc.identifier.pmid | 33392845 | - |
dc.identifier.url | https://link.springer.com/article/10.1007%2Fs10549-020-06043-0 | - |
dc.subject.keyword | Brain metastasis | - |
dc.subject.keyword | Brain-directed treatment | - |
dc.subject.keyword | Breast cancer | - |
dc.subject.keyword | Tumor molecular subtype | - |
dc.subject.keyword | Whole-brain radiotherapy | - |
dc.contributor.alternativeName | Kim, Yong Bae | - |
dc.contributor.affiliatedAuthor | 김용배 | - |
dc.contributor.affiliatedAuthor | 장지석 | - |
dc.citation.volume | 186 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 453 | - |
dc.citation.endPage | 462 | - |
dc.identifier.bibliographicCitation | BREAST CANCER RESEARCH AND TREATMENT, Vol.186(2) : 453-462, 2021-04 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.